COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis

BACKGROUND: Immune-related adverse events due to immune checkpoint inhibitors (ICIs) are not always effectively treated using glucocorticoids and it may negatively affect the antitumor efficacy of ICIs. Interventional studies of alternatives to glucocorticoids are lacking. We examined whether interl...

Descripción completa

Detalles Bibliográficos
Autores principales: Holmstroem, Rikke Boedker, Nielsen, Ole Haagen, Jacobsen, Søren, Riis, Lene Buhl, Theile, Susann, Bjerrum, Jacob Tveiten, Vilmann, Peter, Johansen, Julia Sidenius, Boisen, Mogens Karsbøl, Eefsen, Rikke Helene Løvendahl, Marie Svane, Inge, Nielsen, Dorte Lisbet, Chen, Inna Markovna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472120/
https://www.ncbi.nlm.nih.gov/pubmed/36096534
http://dx.doi.org/10.1136/jitc-2022-005111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472120/
https://www.ncbi.nlm.nih.gov/pubmed/36096534
http://dx.doi.org/10.1136/jitc-2022-005111

Ejemplares similares